Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 448 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR The Switch of Breast Tumours to HER2-Low Status in Recurrence Might... May 8, 2021 Researchers Discover Potential Way to Hit Elusive Target in Pancreatic Cancer April 4, 2019 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June June 14, 2024 Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... March 6, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel EMA Recommends Granting a Marketing Authorisation for Elacestrant Personalised blood test could help predict which lung cancers might return Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma...
